The development of immune checkpoint inhibitor (ICI) therapy, particularly with antibodies blocking programmed cell death-1/programmed cell death ligand-1 (anti-PD-1/PD-L1 therapy), was a milestone achievement in tumor therapy8. The gene discussed is PDCD1; the disease is neoplasm.